GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) is having an incredibly strong start to the trading session in the pre-market hours this morning after announcing positive clinical results. The results come from the company’s Phase 3 clinical trial of EPIDIOLEX, a treatment that is derived from cannabis and is being assessed as an option for epilepsy. Today, we’ll talk about:
- The data;
- what we’re seeing from GWPH stock as a result; and
- what we’ll be watching for ahead.
GWPH Climbs On Positive Clinical Data
As mentioned above, GW Pharmaceuticals is having an incredibly strong start to the trading session this morning after the company announced positive top-line results from a clinical study. In a press release issued early this morning, the company provided positive results from the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of EPIDIOLEX.
EPIDIOLEX is a cannabidiol or CBD drug that is derived from cannabis. The treatment was designed by GWPH as an option for the treatment of seizures. In this particular study, the treatment showed strong efficacy and safety data in seizures associated with Dravet syndrome. Dravet syndrome is a rare, yet debillitating form of childhood-onset epilepsy.
The data showed that when EPIDIOLEX was added to teh current treatment, patients achieved a reduction in convulsive seizures for both dose levels with a high statistical significance when compared to placebo. Key secondary endpoints also showed statistically significant improvements. In a statement, Ian Miller, M.D., Director of the Epilepsy and Neurophysiology Program at Nicklaus Children’s Hospital and lead investigator on the trial, had the following to offer:
The positive outcome in this second trial of EPIDIOLEX in patients with Dravet syndrome further reinforces the effectiveness of this newly available medicine in this particularly difficult to treat, childhood-onset epilepsy… The totality of data from the controlled clinical trials completed for EPIDIOLEX have shown clinically meaningful seizure reductions and a consistent safety and tolerability profile. I am excited that this recently approved and important new treatment option is now available for my patients.
The above statement was followed up by Justin Gover, CEO at GWPH, here’s what he had to offer:
The positive results from this trial follow the recent FDA approval, DEA rescheduling and U.S. launch of EPIDIOLEX for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut Syndrome in patients two years and older. These data show an effective dose range in Dravet syndrome that is consistent with our FDA approved label, and which allows for dosing flexibility to address individual patient needs… We are proud to have recently launched EPIDIOLEX, the first FDA-approved plant-derived cannabinoid medicine and are excited about its potential to help the lives of patients and their families.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news leads to moves. In the case of GW Pharmaceuticals, the news proved to be overwhelmingly positive. After all Dravet syndrome is overwhelmingly difficult to treat, and the company’s treatment seems to be yielding positive results in this space. So, it’s not surprising to see that excited investors are pushing the stock on a run for the top in the market this morning. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:41), GWPH is trading at $129.26 per share after a gain of $5.21 per share or 4.20% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on GWPH. In particular, we’re interested in following the story surrounding the company’s continued work to bring EPIDIOLEX to market. With the overwhelmingly positive results that were published today, the story is becoming more and more exciting. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!